Lyme vaccine broadly effective; Valneva shares fall
Pfizer and Valneva said an experimental Lyme disease vaccine was broadly effective, but Valneva's stock fell after the trial failed to meet its primary endpoint.
Pfizer and Valneva announced Monday that an experimental vaccine for Lyme disease was broadly effective. Valneva's shares fell because the clinical trial did not reach its main goal.